|
|
|
|
| LEADER |
01568nam a2200253 u 4500 |
| 001 |
EB002002304 |
| 003 |
EBX01000000000000001165205 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Brett, Kendra
|
| 245 |
0 |
0 |
|a Bacille Calmette-Guerin vaccination
|h Elektronische Ressource
|b a review of clinical effectiveness and guidelines
|c Kendra Brett, Melissa Severn
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2020, April 02, 2020
|
| 300 |
|
|
|a 1 PDF file (45 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Severn, Melissa
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK563004
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The Bacillus Calmette-Guérin (BCG) vaccine is the only vaccine against TB in general use, and it is one of the most widely administered vaccines. Nevertheless, there are still some questions with regards to the effectiveness of the BCG vaccine, particularly, the duration of the effect, and the ability to protect against pulmonary TB in adults. This report is a component of a larger CADTH Condition Level Review on TB. A condition level review is an assessment that incorporates all aspects of a condition, from prevention, detection, treatment, and management
|